A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wyrażenie świadomej zgody przed rozpoczęciem jakichkolwiek badań związanych z badaniem.
- •Osoby pełnoletnie (w wieku co najmniej 18 lat lub więcej, jeśli prawo stanowi inaczej).
- •Potwierdzony typ raka płuca: drobnokomórkowy rak płuca w zaawansowanym stadium, który wymaga leczenia pierwszego rzutu.
- •Pacjenci w Grupie 1: ukończyli 4 cykle leczenia pierwszego rzutu (karboplatyna, etopozyd, atezolizumab) i u których choroba nie postępuje.
- •Pacjenci w Grupie 2: nie byli wcześniej leczeni z powodu tego raka.
- •Pacjenci w Grupie 2: posiadają zmianę nowotworową widoczną w badaniach obrazowych (CT lub MRI), która może być mierzona.
- •Pacjenci w Grupie 2: posiadają zmianę, z której można pobrać wycinek do biopsji, i zgadzają się na jej pobranie przed leczeniem i w trakcie leczenia.
- •Stan ogólny pacjenta oceniany jako dobry (ECOG PS ≤ 1).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (58)
University of Alabama -Birmingham
Birmingham, United States
Mayo Clinic Arizona
Phoenix, United States
David Geffen School of Medicine
Los Angeles, United States
Hoag Memorial Hospital Presbyterian
Newport Beach, United States
Mayo Clinic-Jacksonville
Jacksonville, United States
Advent Health Orlando
Orlando, United States
Moffitt Cancer Center
Tampa, United States
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Chicago, United States
Henry Ford Hospital
Detroit, United States
Regents of the University of Minnesota
Minneapolis, United States
Mayo Clinic
Rochester, United States
Dartmouth-Hitchcock Medical Center
Lebanon, United States
Astera Cancer Care
East Brunswick, United States
John Theurer Cancer Center At Hackensack Umc
Hackensack, United States
New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone
Mineola, United States
NYU Langone Hospital - Long Island
Mineola, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Columbia University Hervert Irving Comprehensive Cancer Center
New York, United States
Montefiore Medical Center
New York, United States
Lancaster General Hospital - Ann B Barshinger Cancer Institute
Lancaster, United States
University of Pennsylvania, Abramson Cancer Center
Philadelphia, United States
Thomas Jefferson University Hospital - Central
Philadelphia, United States
Scri Oncology Partners
Nashville, United States
Next Virginia
Fairfax, United States
Northwest Cancer Specialists, P.C.-Vancouver
Vancouver, United States
Medical College of Wisconsin
Milwaukee, United States
Hopital Albert Calmette - Chu Lille
Lille, France
Centre Léon Bérard
Lyon, France
Hôpital de la Timone
Marseille, France
Institut Curie - Site de Paris
Paris, France
Hopital Tenon
Paris, France
Chu Rennes - Hopital Pontchaillou
Rennes, France
CHU Nantes - Hôpital Guillaume et René Laënnec
Saint-Herblain, France
Hôpital Foch
Suresnes, France
Institut Gustave Roussy
Villejuif, France
NHO Himeji Medical Center
Himeji-shi, Japan
Kansai Medical University Hospital
Hirakata-shi, Japan
National Cancer Center Hospital East
Kashiwa, Japan
The Cancer Institute Hospital of Jfcr
Kōtoku, Japan
Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital
Kumamoto, Japan
Shizuoka Cancer Center
Nagaizumi-cho, Japan
Niigata Cancer Center Hospital
Niigata, Japan
Okayama University Hospital
Okayama, Japan
Kindai University Hospital
Ōsaka-sayama, Japan
Tokushima University Hospital
Tokushima, Japan
Fujita Health University Hospital
Toyoake-shi, Japan
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitari Vall D'Hebron
Barcelona, Spain
Ico Girona - Hospital Universitari de Girona Dr Josep Trueta
Girona, Spain
ICO l'Hospitalet - Hospital Duran i Reynals
L'Hospitalet de Llobregat, Spain
Hospital General Universitario Gregorio Marañon
Madrid, Spain
Hospital Universitario Ramon Y Cajal
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Next Madrid
Madrid, Spain
Hospital Regional Universitario de Malaga
Málaga, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Hospital Universitario Virgen Del Rocio
Seville, Spain
Hospital Alvaro Cunqueiro
Vigo, Spain
Trial contact
(US) Daiichi Sankyo Contact for Clinical Trial Information
(Asia) Daiichi Sankyo Contact for Clinical Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/2/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.